The leader in irreversible electroporation technology plans to expand the use of technology in various indications
Medical technology company REMD (Chinese: 睿刀医疗) announced that it had completed an over CNY 100 million Series A+ funding round, which was led by Silicon Paradise (Chinese: 天堂硅谷) and followed by Detong Capital (Chinese: 德同资本), and Qianzhan Capital (Chinese: 乾瞻资本). Close A and Bnaghua Finance (Chinese: 邦华金融) acted as the co-financial advisers. After this financing, REMD will accelerate the layout and innovation of its product in the fields of Benign Prostatic Hyperplasia (BPH), cardiac pulsed field ablation (PFA), and liver cancer. Meanwhile, REMD will also improve the availability and affordability of its approved products.
Founded in 2016, REMD is an innovative developer of irreversible electroporation technology, focusing on the R&D, production and sales of the third type of medical equipment for the treatment of tumors with high-frequency irreversible electroporation as its core technology.
Compound steep pulse treatment device REMD-G1 is its main product and is the first approved product for the treatment of prostate cancer in the world. This device could cause cell irreversible electroporation, which leading necrosis of tumor cells. It also has the ability to prevent nerve, vessel, urethral and capsule unnecessary injury beside the ablation area. After the first application of irreversible electroporation technology in prostate cancer, the device has rapidly applied by hospitals and achieved commercialization. In 2022, CFDA has accepted its PFA device REMD-G5's application for special examination and approval procedures for innovative medical products.
REMD's competitors include Pulsecare (Chinese: 迈微医疗), JJET (Chinese: 锦江电子) and Surgnova(Chinese: 赛诺微医疗).